Client
- Name
- BIOGEN
- Location
- District of Columbia · United States of America
Registrant
- Firm
- BIOGEN
- Location
- WASHINGTON, District of Columbia, United States of America
Lobbying activities
7 issuesMedicare/Medicaid
Drug cost and pricing policy issues Issues regarding coverage, coding, and reimbursement issues Issues regarding Alzheimer's treatments Issues related to the 340B program Medicare reform
LobbyistsJONATHAN CAUSEY · DANIEL HARDER · ms KATHLEEN KONKA
TargetedSENATE · HOUSE OF REPRESENTATIVES · Centers For Medicare and Medicaid Services (CMS)
Health Issues
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act
LobbyistsJOHN RAYMOND GIBSON · JONATHAN CAUSEY · TYLER HANSON · DANIEL HARDER · mx ALI LAKHANI · ms KATHLEEN KONKA
TargetedSENATE · HOUSE OF REPRESENTATIVES · Centers For Medicare and Medicaid Services (CMS)
Pharmacy
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act